Drugs / Tarloxotinib
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05313009 | Mar 2022 → Jul 2023 | non-small cell lung carcinoma | Medical University of South Carolina | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03805841 | Mar 2019 → Apr 2021 | non-small cell lung carcinoma | Rain Oncology Inc | Terminated | No outcome recorded |
| Phase 2 | NCT02449681 | Aug 2015 → Jan 2017 | head and neck squamous cell carcinoma | Rain Oncology Inc | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tarloxotinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03805841 ↗ |
| Known as | TH-4000 | “TH-4000 (Tarloxotinib)” NCT02449681 ↗ |
| Action | Inhibit | “an irreversible pan-ErbB tyrosine kinase inhibitor” PMID 35435625 ↗ Apr 2022 |
| Route | Intravenous | “will be administered by IV infusion over 60 minutes” NCT02449681 ↗ |